NCT06098300 Effects of Change in Blood Pressure on Retinal Capillary Rarefaction in Patients With Arterial Hypertension
| NCT ID | NCT06098300 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Vienna |
| Condition | Arterial Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2025-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2023-09-01 with a primary completion date of 2025-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate whether in patients with initially poorly-controlled arterial hypertension, structural and functional differences in the retina and choroid remain after achieving a well-controlled blood pressure.
Eligibility Criteria
Inclusion Criteria: * Men and Women aged ≥ 18 years * Signed informed consent * Apart from hypertensive retinopathy, normal ophthalmic findings * Non-Smokers * Patients with initially diagnosed or pre-existing mild to moderate primary arterial hypertension (systolic office blood pressure ≥ 140 mmHg and/or diastolic office blood pressure ≥ 90 mmHg) * Planned initiation of antihypertensive medication or planned adaption of antihypertensive medication by the Department of Cardiology * Subject agrees to perform regular blood pressure self-measurements and to document blood pressure values in a diary Exclusion Criteria: * Participation in a clinical trial in the three weeks preceding the study * Blood donation in the three weeks preceding the study * Symptoms of a clinically relevant illness in the three weeks preceding the study * History of family history of epilepsy * Secondary hypertension (e.g.: hyperaldosteronism, pheochromocytoma, renal artery stenosis, renal parenchymal diseases, Cushing-syndrome, Coarctatio aortae) * History of hypertensive encephalopathy or intracerebral bleeding * Diabetes mellitus Type 1 or Type 2 * Pregnant or breast-feeding women * Women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06098300 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Arterial Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06098300 currently recruiting?
Yes, NCT06098300 is actively recruiting participants. Contact the research team at klin-pharmakologie@meduniwien.ac.at for enrollment information.
Where is the NCT06098300 trial being conducted?
This trial is being conducted at Vienna, Austria.
Who is sponsoring the NCT06098300 clinical trial?
NCT06098300 is sponsored by Medical University of Vienna. The trial plans to enroll 30 participants.